Fig. 1.

Optimization of (A) the primary antibody, anti-MMP-3 (Ab₁) and (B) the secondary antibody, anti-MMP-3 (Ab₂) concentrations; (a) the complete immunoassay using 4.0 ng mL⁻¹ MMP-3 concentration and (b) controls with 0 ng mL⁻¹ MMP-3. In (A), the secondary antibody, Ab₂ (tracer), concentration was kept fixed at 200 ng mL⁻¹ in both the controls and the samples while in (B), the optimum Ab₁ (200 ng mL⁻¹) concentration was used to optimize Ab₂ concentration.